On a per-share basis, the Cambridge, Britain-based company said it had net income of 59 cents. Earnings, adjusted for amortization costs and non-recurring costs, came to 81 cents per share.

The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 71 cents per share.

The pharmaceutical posted revenue of $7.32 billion in the period.

Astrazeneca shares have increased nearly 3% since the beginning of the year. The stock has risen slightly more than 1% in the last 12 months.